Literature DB >> 1833332

Forecasting the medical care costs of the HIV epidemic: 1991-1994.

F J Hellinger1.   

Abstract

This is the first paper to forecast the cost of medical care for all people with the human immunodeficiency virus (HIV). Previous studies have concentrated on the cost of treating people with AIDS (PWAs). It is estimated that the average cost of treating a person with HIV without AIDS is $5,150 per year, and that the average cost of treating a PWA is $32,000 per year ($24,000 for inpatient hospital care and $8,000 for other services). The lifetime cost of medical care for a PWA is calculated to be $85,333. This is higher than many previous estimates of lifetime costs due to increased longevity and the diffusion of costly outpatient drugs. The cost of treating all people with HIV in 1991 is forecast to be $5.8 billion. Of this amount, it is estimated that $1.4 billion will be spent on people with HIV without AIDS, and the remaining $4.4 billion on PWAs. It is forecast that the cost of treating all people with HIV will increase 21% each year between 1991 and 1994, and that $10.4 billion will be spent on treating all people with HIV in 1994.

Entities:  

Mesh:

Year:  1991        PMID: 1833332

Source DB:  PubMed          Journal:  Inquiry        ISSN: 0046-9580            Impact factor:   1.730


  16 in total

1.  First year of AIDS services delivery under Title I of the Ryan White CARE Act.

Authors:  G S Bowen; K Marconi; S Kohn; D M Bailey; E P Goosby; S Shorter; S Niemcryk
Journal:  Public Health Rep       Date:  1992 Sep-Oct       Impact factor: 2.792

2.  Health services needs and related costs for HIV care.

Authors:  D P Andrulis; V B Weslowski
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

3.  "Optimal" cost-effectiveness analyses?

Authors:  S D Nightingale
Journal:  J Gen Intern Med       Date:  1992 May-Jun       Impact factor: 5.128

4.  HIV infection treatment costs under Medicaid in Michigan.

Authors:  D J Solomon; A J Hogan
Journal:  Public Health Rep       Date:  1992 Jul-Aug       Impact factor: 2.792

Review 5.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

6.  The pharmacoeconomics of HIV disease.

Authors:  L A Lynn; K A Schulman; J M Eisenberg
Journal:  Pharmacoeconomics       Date:  1992-03       Impact factor: 4.981

7.  Contemporary costs of HIV healthcare in the HAART era.

Authors:  Kelly A Gebo; John A Fleishman; Richard Conviser; James Hellinger; Fred J Hellinger; Joshua S Josephs; Philip Keiser; Paul Gaist; Richard D Moore
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

Review 8.  Defining and measuring the costs of the HIV epidemic to business firms.

Authors:  P G Farnham
Journal:  Public Health Rep       Date:  1994 May-Jun       Impact factor: 2.792

9.  Partner notification for control of HIV: results after 2 years of a statewide program in Utah.

Authors:  A T Pavia; M Benyo; L Niler; I Risk
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

10.  HIV prevention in prisons and jails: obstacles and opportunities.

Authors:  S Polonsky; S Kerr; B Harris; J Gaiter; R R Fichtner; M G Kennedy
Journal:  Public Health Rep       Date:  1994 Sep-Oct       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.